PMID- 33285720
OWN - NLM
STAT- MEDLINE
DCOM- 20201223
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 49
DP  - 2020 Dec 4
TI  - Gegen huangqin huanglian decoction for children rotavirus enteritis: A protocol 
      for systematic review and meta-analysis.
PG  - e23376
LID - 10.1097/MD.0000000000023376 [doi]
LID - e23376
AB  - BACKGROUND: Rotavirus infection is the main cause of severe dehydration enteritis 
      in children under 5 years old. It gives rise to malnutrition and even death in 
      children even though there were rotavirus vaccines. However, there is no 
      effective anti-virus drugs for rotavirus, supporting treatments are used in the 
      clinics. Traditional Chinese medicine (TCM) has been treating diarrhea for many 
      years. Gegen Huangqin Huanglian Decoction (GHHD)is a classic prescription for 
      diarrhea in TCM. With the development of clinical trials and basic studies, GHHD 
      has been proved that a good curative effect on diarrhea. Therefore, a systematic 
      review is necessary to improve available evidence for GHHD in therapy of children 
      under 5 years old with rotavirus enteritis. METHODS: Different studies from 
      various databases will be involved in this study. Only randomized controlled 
      trials of rotavirus enteritis patients diagnosed with Guidelines for the 
      Treatment of Acute Gastroenteritis in Outpatient Pediatrics, which released by 
      the Washington International Children's Medical Center, Zhu Futang's Practical 
      Pediatrics (7 th Edition), and the 2016 clinical practice guidelines for children 
      with acute infectious diarrhea in China. We will search the literature in the 
      databases from China Conference Paper Database, manual searching. Electronic 
      database includes PubMed, Embase, Cochrane Library, Web of Science, CNKI (China 
      National Knowledge Internet), WanFang, VIP (Chongqing VIP), and CBM (China 
      Biomedical Literature CDROM Database). The primary outcomes include the total 
      effective rate, the time of stopping diarrhea, the level of IL-6 serum 
      concentration, fecal microflora ratio, the conversion of fecal rotavirus antigen. 
      The secondary outcomes include clinical efficacy and the quantitative integral of 
      TCM symptom, recovery time of stool character, treatment period. Besides, 
      incidence of adverse events (such as irritation and toxicity) and costs will be 
      also considered. Data will be extracted by 2 researchers independently, risk of 
      bias of the meta-analysis will be evaluated based on the Cochrane Handbook for 
      Systematic Reviews of Interventions. All data analysis will be conducted by data 
      statistics software Review Manager V.5.3 and Stata V.12.0. RESULTS: This study 
      will synthesize and provide high-quality evidence based on the data of the 
      currently published GHHD for the treatment of children rotavirus enteritis, in 
      terms of the total effective rate, the time of stopping diarrhea, the level of 
      IL-6 serum concentration, fecal microflora ratio, stool rotavirus antigen, 
      clinical efficacy and the quantitative integral of TCM symptom, recovery time of 
      stool character, treatment period, and safety. CONCLUSION: This systematic review 
      aims to evaluated the benefits and harms of GHHD for the treatment of children 
      rotavirus enteritis reported in randomized controlled trials, and provide more 
      options for clinicians and patients to treat children rotavirus enteritis. 
      REGISTRATION NUMBER: INPLASY2020100023.
FAU - Wu, Yifang
AU  - Wu Y
AUID- ORCID: 0000-0003-3841-9133
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 
      Province, China.
FAU - Tu, Xiang
AU  - Tu X
FAU - Liang, Xiao
AU  - Liang X
FAU - Chen, Jing
AU  - Chen J
FAU - Wan, Xuemei
AU  - Wan X
FAU - Zhang, Tianhong
AU  - Zhang T
FAU - Jiang, Jingrong
AU  - Jiang J
FAU - Zhong, Sen
AU  - Zhong S
AUID- ORCID: 0000-0003-3841-9133
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-6)
RN  - 0 (huanglian)
SB  - IM
MH  - Child, Preschool
MH  - Diarrhea/*drug therapy/etiology/virology
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Feces/virology
MH  - Humans
MH  - Infant
MH  - Interleukin-6/blood
MH  - Medicine, Chinese Traditional/methods
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Rotavirus Infections/complications/*drug therapy
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7717832
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/12/09 06:00
MHDA- 2020/12/29 06:00
PMCR- 2020/12/04
CRDT- 2020/12/08 01:02
PHST- 2020/12/08 01:02 [entrez]
PHST- 2020/12/09 06:00 [pubmed]
PHST- 2020/12/29 06:00 [medline]
PHST- 2020/12/04 00:00 [pmc-release]
AID - 00005792-202012040-00057 [pii]
AID - MD-D-20-09895 [pii]
AID - 10.1097/MD.0000000000023376 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Dec 4;99(49):e23376. doi: 10.1097/MD.0000000000023376.